Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, preliminary prospectus27 Mar 2006
Genmab, final prospectus27 Mar 2006
Genmab, articles of association dated March 21 200622 Mar 2006
Genmab, Reports ACR50 and ACR70 Results in HuMax-CD20 Study to Treat RA21 Mar 2006
Genmab, Announces Update on AMG 714 Program with Amgen10 Mar 2006
Genmab, articles of association dated March 8, 20069 Mar 2006
InvestorService: Genmab, to Present at Lehman Brothers' Ninth Annual Global Healthcare Conference8 Mar 2006
Genmab, 77% Achieve ACR20 with Genmab's HuMax-CD20 in Rheumatoid Arthritis Study
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
8 Mar 2006
Genmab, Clarification of Stock Exchange Notice No. 10 of March 2, 20063 Mar 2006
Genmab, Capital Increase In Genmab As A Result Of Employee Warrant Exercise2 Mar 2006
Genmab, Grant Of Warrants In Genmab A/S2 Mar 2006
Genmab, notification from major shareholder (section 29) from Serono B.V.28 Feb 2006
  • Previous
  • 1
  • More pages
  • 128
  • 129
  • 130
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863